RESEARCH ARTICLE

Application of collagen triple helix repeat containing-1 and mitotic spindle apparatus antibody in small cell lung cancer diagnosis

Yuhan Liu¹,²,³ | Tingting Hu¹,²,³ | Xu Li¹,² | Xiaohang Li¹,² | Jianlin Yu¹,² | Yang Wu¹,² | Simei Chen¹,² | Liming Tan¹,²

¹Department of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang, China
²Jiangxi Province Key Laboratory of Laboratory Medicine, Nanchang, China
³Graduate Students in the School of Public Health of Nanchang University, Nanchang, China

Correspondence
Liming Tan, Department of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, NO.1 Minde Road, Donghu District, Nanchang, Jiangxi, China.
Email: ndefy84029@ncu.edu.cn

Abstract

Background: The clinical significance of serum collagen triple helix repeat protein-1 (CTHRC1) and mitotic spindle apparatus antibody (MSA) in the diagnosis of small cell lung cancer (SCLC).

Methods: Of the 229 lung tumor patients selected, 62 patients were divided into SCLC, 94 patients with non-small cell lung cancer (NSCLC), and 73 patients with benign lung disease (BLD). The health controls (HC) had a span of 66 cases with normal physical condition. The serum extracted from each participator and enzyme-linked immunosorbent assay was adopted for measuring the serum CTHRC1 and MSA; in the meantime, automatic electrochemiluminescence immunoassay was used for the quantitative determination of serum NSA and CEA. And then, the differences in serum CTHRC1, MSA, NSE, and CEA were compared among involved groups.

Results: ① Compared with other groups, the concentrations of CTHRC1, MSA, and NSE showed a marked increase in the group of SCLC (all \( p < 0.01 \)). Especially for SCLC patients with lymph node metastasis, CTHRC1 provided a notably higher level than those without metastasis. ② CTHRC1 and MSA established a diagnostic criterion with the specificity of 90.99% and 86.27% for SCLC, respectively. ③ In series, the specificity of CTHRC1 and NSE was the highest (99.30%), while MSA and NSE had the highest sensitivity (96.72%) in parallel. ④ Both CTHRC1 and MSA were hazardous factors interconnected with SCLC.

Conclusion: Serum CTHRC1 and MSA had a more exciting prospect of application. When used in conjunction with NSE and CEA, they could optimize the clinical diagnosis value of SCLC.

KEYWORDS
collagen triple helix repeat containing-1, mitotic spindle apparatus antibody, neuron-specific enolase, non-small cell lung cancer, small cell lung cancer

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.

Received: 11 February 2022 | Revised: 7 March 2022 | Accepted: 23 March 2022
DOI: 10.1002/jcla.24412

https://doi.org/10.1002/jcla.24412

J Clin Lab Anal. 2022;36:e24412.
https://wileyonlinelibrary.com/journal/jcla

Yuhan Liu and Tingting Hu contributed equally to this work and should be considered co-first authors.
1 | INTRODUCTION

Small cell lung cancer (SCLC), accounting for 10%–15% of lung cancer, is a malignant neuroendocrine tumor dating from bronchial mucosa or glands. But it is worth reminding that a large number of early SCLC patients do not have any keynote manifestations, and SCLC is frequently diagnosed during its final stage with widespread metastasis and invasion, which is rather prone to recur and make the treatment fail. In fact, the 5-year survival rate is only about 10%. As a consequence, more promising serological markers with excellent specificity or sensitivity are urgently demanded for increasing the clinical diagnostic value of SCLC and monitoring early treatment response. Neuron-specific enolase (NSE), a kind of tumor marker bounded up with SCLC, is routinely used in clinical practice. When detected with carcinoembryonic antigen (CEA), it is helpful for differential diagnosis, prognosis, and follow-up of SCLC patients. The drawback of NSE and CEA, of course, is lacking sensitivity. In some circumstances, such as in a few SCLC patients with limited stage, the NSE level without increasing and CEA is also abnormally elevated in other tumor types. Up to now, ideal serum markers have not been found yet. In order to gain a preferable specificity or sensitivity, it is usually combined with two or more serum markers in the diagnosis of SCLC. The prophase work showed that abnormal production of mitotic spindle apparatus antibody (MSA) in serum was conducive to the early diagnosis of SCLC. Collagen triple helix repeat indent-1 (CTHRC1), aberrant expression in many kinds of tumor tissues especially in NSCLC, has been turned out to be a tumor-related oncogene. However, the expression of CTHRC1 in serum of lung cancer patients has not been reported. For this reason, the study detected and investigated CTHRC1, MSA, NSE, and CEA levels in serum of SCLC, NSCLC, benign lung diseases (BLD), and healthy control (HC) patients diagnosed in the Second Affiliated Hospital of Nanchang University. Concrete reports are shown below.

2 | MATERIALS AND METHODS

2.1 | Research objects

The capacity of this study contained 62 patients with SCLC, 94 patients with NSCLC, and 73 patients with BLD who were diagnosed in the Second Affiliated Hospital of Nanchang University from October 2019 to June 2021. There were 37 male and 25 female patients with SCLC, which were further classified into 43 cases with lymph node metastasis and 19 cases without, aged from 43 to 78 years old, with an average of 61.95 ± 8.442 years. The age of NSCLC patients, consisting of 58 males and 36 females, was between 34 and 84 years old, with an average of 59.95 ± 9.964 years, while BLD patients, including 40 males and 33 females, were in the 27–76 age range with an average of 60.26 ± 9.864 years. The clinical diagnostic criteria for diseases in this study were consistent with relevant diagnostic and treatment guidelines established by the International Union Against Cancer (UICC). Sixty-six healthy controls who passed routine examinations at the same period were 37 males and 29 females, aged from 46 to 78 years, with an average of 59.58 ± 7.405 years. The differences were not statistically significant in age and gender among the four groups (p > 0.05). According to the Declaration of Helsinki, all the participants had reached an oral agreement or contracted informed consent. And this research has got past the censors by the Ethics Committee of the Second Affiliated Hospital of Nanchang University (Ethical code: No. Review-2019-049).

2.2 | Inclusion and exclusion criteria

2.2.1 | Inclusion criteria

1) Lung cancer patients were identified by histopathological or cytological examination. 2) Clinical and laboratory information completed. 3) Healthy controls without abnormalities in routine examination, especially autoimmune disease. 4) Informed and voluntary participation.

2.2.2 | Exclusion criteria

1) Non-primary pulmonary tumors or combination of other tumors. 2) Associated with neurological and endocrine metabolic system diseases, for instance, hyperthyroidism. 3) Has received an extended period of standardized therapeutic intervention or empirical treatment. 4) Poor adherence.

2.3 | Methods

2.3.1 | Collection and storage of specimens

About 3 ml elbow venous blood was collected from all subjects with empty stomach in the early morning and placed in blood collection tubes containing procoagulants and separator gel. The blood was allowed to stand for 10 min at room temperature before centrifugation at 3500 rpm/min for 15 min at 4°C. The upper serum was then sucked out carefully and transferred into a new 2.0 ml microcentrifuge tube. Only serum samples without visible hemolysis and lipemia were placed in the −20°C freezer prior to measurement.

2.3.2 | Experimental methods

 Serum levels of CTHRC1 (Huzhen Industrial Co. Ltd.) and MSA (R&D Systems Inc.) were estimated by enzyme-linked immunosorbent assays (ELISAs). Tumor biomarkers, including NSE and CEA, were assessed on an automatic electrochemistry luminescence
immunity analyzer (Roche), and the reagents were supplied by Roche Diagnostics Co., Ltd. All relevant determination operations strictly followed the manufacturer’s protocol and the quality management process of the Second Affiliated Hospital of Nanchang University. The intra- and inter-laboratory coefficients of variation were consistently satisfactory throughout the measurements.

2.4 | Statistical analysis

SPSS25.0 and MedCalc statistical software were used to basically describe and perform statistical analyses of the detection results, and plotting was carried out using GraphPad Prism software. The normal distribution and homogeneity of variances of continuous variables were assessed by the Kolmogorov–Smirnov (K-S) test and Levene statistic. Data with normal distribution were presented in the form of \( \bar{X} \pm s \), and skewed distribution data were presented as median with interquartile range. One-way ANOVA was conducted for comparison among groups of normally distributed data, while Kruskal–Wallis (K-W) test for the data of non-parametric distribution. Chi-square test was used to identify the differences between classification data groups. The receiver operating characteristic (ROC) curves were plotted to evaluate the diagnostic value. Logistic regression models were used to work out odds ratios (ORs) and 95% confidence intervals (CIs) interrelating serum marker concentration and SCLC risk. The difference was accepted as statistically significant when \( p < 0.05 \).

3 | RESULTS

3.1 | Differences in serological index expression levels among subjects

The levels of serum CTHRC1, MSA, NSE, and CEA in patients with SCLC, NSCLC, BLD, and HC are shown in Table 1. As we can see, compared with the other three groups, the results of CTHRC1, MSA, and NSE were generally elevated in SCLC patients according to the performances of one-way ANOVA test and Kruskal–Wallis (K-W) test (\( p < 0.01 \)). Meanwhile, the CEA level in the SCLC group was higher than that of the BLD group and HC group, but no significant difference was found with that of the NSCLC group (\( p > 0.05 \)). The detailed results can be found in Table 1.

3.2 | The association between CTHRC1 and lymph node metastasis in SCLC

Small cell lung cancer patients were divided into two groups, with metastasis positive in 43 cases (69.35% positive expression rate) and metastasis negative in 19 cases, on the basis of the condition of lymph node metastasis. We noticed that patients with lymph node metastasis showed higher CTHRC1 levels with 380.41 (309.64–516.49) (ng/ml) compared with those without lymph node metastasis with 217.93 (172.46–267.05) (ng/ml) (\( p < 0.01 \); Figure 1).

3.3 | Diagnostic performance of serological indexes in SCLC patients

To compare different sensitivities and specificities, we used receiver operating characteristic (ROC) curve analysis for each index. The outcomes demonstrated that the sensitivities of CTHRC1, MSA, NSE, and CEA in diagnosing SCLC were 58.06%, 77.42%, 85.48%, and 69.35%, respectively. For the corresponding specificities, there were 90.99%, 86.27%, 92.27%, and 64.38%, respectively. The areas under the curve (AUC) for CTHRC1 and MSA were around 0.808 and 0.906 with suggested cut-off values of 319.06 ng/ml and 56.07 pg/ml, respectively, which were the most discriminative to predict SCLC. More detailed results are reported in Table 2 and Figure 2.

3.4 | Diagnostic value of pairwise combination of indicators

The performance of each two indicators ligated in parallel or tandem showed that CTHRC1 obtained the highest specificity of 99.30% when connected with NSE in tandem. The sensitivity of diagnostic value was highest (96.72%) when MAS linked with NSE in parallel. See Table 3 for details.

### TABLE 1 Comparison of the levels of biochemical indicators in each group

| Indicator        | SCLC (ng/ml)          | NSCLC (ng/ml)          | BLD (ng/ml)          | HC (ng/ml)          | \( p \) value |
|------------------|-----------------------|------------------------|----------------------|---------------------|--------------|
| CTHRC1 (ng/ml)   | 365.80 ± 185.06\( ^a \)| 245.75 ± 74.12\( ^a \) | 146.01 ± 61.89       | 167.22 ± 83.80      | <0.01        |
| MSA (pg/ml)      | 92.68 ± 41.86\( ^a \) | 50.71 ± 19.76\( ^a \) | 21.99 ± 11.98        | 20.69 ± 10.89       | <0.01        |
| NSE (ng/ml)      | 32.18 ± 16.35\( ^a \) | 9.99 ± 4.76\( ^a \)   | 4.53 ± 1.83          | 3.81 ± 1.61         | <0.01        |
| CEA (ng/ml)      | 3.52(1.93–11.99)\( ^a \)| 2.74(1.42–6.86)\( ^a \)| 1.54(0.89–2.80)      | 1.32(0.77–1.93)     | <0.01        |

Note: \( p < 0.01 \): \( ^a \) compared with BLD and HC; \( ^* \) compared with NSCLC; Results are given as mean ± standard deviation or median (25th–75th percentiles). The difference was analyzed by one-way ANOVA test or Kruskal–Wallis (K-W) test.

Abbreviations: BLD, benign lung diseases; CEA, carcino-embryonic antigen; CTHRC1, collagen triple helix repeat containing-1; HC, healthy control; MSA, mitotic spindle apparatus antibody; NSCLC, non-small cell lung cancer; NSE, neuron-specific enolase; SCLC, small-cell lung cancer.
Investigated the potential risk factors for diagnosing SCLC by binary logistic regression analysis

Binary logistic regression analysis was constructed to determine the risk factors associated with SCLC, and the results showed that CTHRC1, MSA, and NSE were the independent risk factors for diagnosing SCLC. As the levels of various indicators increased, the odds of developing SCLC also increased. As shown in Table 4.

TABLE 2 The clinical values of four serum biomarkers in diagnosing SCLC

| Indicator | AUC  | Youden Index | Cut-off | Sensitivity (%) | Specificity (%) |
|-----------|------|--------------|---------|----------------|-----------------|
| CTHRC1 (ng/ml) | 0.808 | 0.491 | 319.06 | 58.06 | 90.99 |
| MSA (pg/ml) | 0.906 | 0.637 | 56.07 | 77.42 | 86.27 |
| NSE (ng/ml) | 0.962 | 0.778 | 14.25 | 85.48 | 92.27 |
| CEA (ng/ml) | 0.709 | 0.337 | 2.43 | 69.35 | 64.38 |

![FIGURE 1](https://via.placeholder.com/150) Association between CTHRC1 and lymph node metastasis in SCLC. Note: ***p < 0.01. Abbreviations: CTHRC1, collagen triple helix repeat containing-1

![FIGURE 2](https://via.placeholder.com/150) Comparison of the diagnostic ability between four indicators by ROC analysis

DISCUSSION

The incidence and death rate of lung cancer shows an upward trend year over year among all malignant tumors. The incidence of lung cancer, which poses a severe threat to human health, ranks highest among all malignant tumors in males and second only to breast cancer in females.\(^6,7\) SCLC, a malignant and invasive tumor, progresses fastest in lung cancer and is most prone to relapse after treatment. Its tumor size, location, surrounding invasion, or complications are closely associated with clinical manifestations. At present, imaging is the fundamental method used for the detection of lung cancer in clinical settings. However, lung biopsy is still the gold standard procedure for diagnosing several lung disorders. But the proposed method displays certain limitations due to more trauma and contraindications during operation. Abnormal expression of serum proteins is well known to occur in the blood during the process of tumor cell proliferation and development. So, the most efficient and straightforward auxiliary method is to detect serological protein in clinical practice. When serological proteins are used in conjunction with multiple tumor markers, the sensitivity or specificity of early diagnosis for SCLC can be markedly improved. It may also yield valuable information for the progression of symptoms and the evaluation of the effectiveness of treatment.

Collagen triple helix repeat indent-1, a secreted glycoprotein, is strongly connected with vascular remodeling, wound healing, and the occurrence of osteoblasts. Several prior studies have confirmed that, as a potentially crucial associated gene of malignancy, CTHRC1 was highly expressed in a broad type of solid tumors, including those of the breast, liver, colorectal tissue, and prostate cancer. Upregulated CTHRC1 has the potential ability to enhance tumor proliferation, invasion, cell adhesion, and metastasis by activating multiple signaling pathways such as Wnt/β-catenin signaling. Furthermore, knockdown of CTHRC1 is beneficial for distinctly inhibiting tumor cells proliferation, migration, and adhesion capacity.\(^12,13\) Xue-li Zhang et al.\(^10\) have discovered through the animal model of colorectal cancer that CTHRC1 released from colorectal cancer cells could promote liver metastasis of tumor and was strongly correlated with macrophage infiltration of the immune system. Combination therapy of CTHRC1 monoclonal antibody and anti-PD-1 mAb is powerfully potent in suppressing metastasis, suggesting that CTHRC1 may be an intrinsic marker of tumor invasiveness and can be used as a potential biomarker to predict early prediction of a tumor. Nuzhat Sial et al.\(^14\) reported that the CTHRC1 mRNA was upregulated in the blood of non-small cell patients and the expression level was closely related to the overall survival of patients. Notably, the association of serum CTHRC1 concentration with lung
In conclusion, CTHRC1 and MSA are highly expressed in serum of SCLC patients, and their combined detection with classical tumor serum markers such as NSE and CEA can ameliorate the sensitivity and specificity for the diagnosis of SCLC, and the level of CTHRC1...
can predict whether there is lymph node metastasis in SCLC. CTHRC1 and MSA are excellent complements of serum markers in SCLC diagnosis.

**CONFLICT OF INTEREST**
The authors declare with no conflicting financial interests relevant to this article.

**AUTHOR CONTRIBUTION**
Yuhan Liu and Tingting Hu: data curation, data analysis, visualization, and manuscript writing/editing. Xu Li and Xiaohang Li: data analysis and interpretation of the results. Jianlin Yu, Yang Wu, and Simei Chen: designed the work and manuscript review. Liming Tan: manuscript writing/editing.

**DATA AVAILABILITY STATEMENT**
The data used and analyzed during the current study are available from the corresponding author on reasonable request.

**ORCID**
Liming Tan https://orcid.org/0000-0002-1888-3476

**REFERENCES**
1. Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?-A review. *Transl Lung Cancer Res*. 2016;5(1):26-38.
2. Lu T, Yang X, Huang Y, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. *Cancer Manag Res*. 2019;11(1):943-953.
3. Tan L, Zhang Y, Jiang Y, et al. The clinical significance of anti-mitotic spindle apparatus antibody (MSA) and anti-centromere antibody (ACA) detected in patients with small cell lung cancer (SCLC). *Am J Clin Exp Immunol*. 2017;6(2):21-26.
4. Ke Z, He W, Lai Y, et al. Overexpression of collagen triple helix repeat containing 1 (CTHRC1) is associated with tumour aggressiveness and poor prognosis in human non-small cell lung cancer. *Oncotarget*. 2014;5(19):9410-9424.
5. Lim W, Ridge CA, Nicholson AG, et al. The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications. *Quant Imaging Med Surg*. 2018;8(7):709-718.
6. Bade BC, Dala CC. Lung cancer 2020: epidemiology, etiology, and prevention. *Clin Chim Acta*. 2020;411(1-2):1-24.
7. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394-424.
8. Li H, Liu W, Zhang X, et al. Cancer-associated fibroblast-secreted collagen triple helix repeat containing-1 promotes breast cancer cell migration, invasiveness and epithelial-mesenchymal transition by activating the Wnt/beta-catenin pathway. *Oncol Lett*. 2021;22(6):814-823.
9. Zhou H, Su L, Liu C, et al. CTHRC1 may serve as a prognostic biomarker for hepatocellular carcinoma. *Onco Targets Ther*. 2019;12(1):7823-7831.
10. Zhang XL, Hu LP, Yang Q, et al. CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-beta receptors in colorectal cancer. *Oncogene*. 2021;40(23):3959-3973.
11. Ma Z, Chao F, Wang S, et al. CTHRC1 affects malignant tumor cell behavior and is regulated by miR-30e-5p in human prostate cancer. *Biochem Biophys Res Commun*. 2020;525(2):418-424.
12. Mei D, Zhu Y, Zhang L, et al. The role of CTHRC1 in regulation of multiple signaling and tumor progression and metastasis. *Mediators Inflamm.* 2020;2020(1):1-13.
13. Jin XF, Li H, Zong S, et al. Knockdown of collagen triple helix repeat containing-1 inhibits the proliferation and epithelial-to-mesenchymal transition in renal cell carcinoma cells. *Oncof Res*. 2016;24(6):477-485.
14. He W, Zhang H, Wang Y, et al. CTHRC1 induces non-small cell lung cancer (NSCLC) invasion through upregulating MMP-7/MMP-9. *BMC Cancer*. 2018;18(1):400-414.
15. Zheng B, Mora RA, Fritzler MJ, et al. Establishment of international autoantibody reference standards for the detection of autoantibodies directed against PML bodies, GW bodies, and NuMA protein. *Clin Chem Lab Med*. 2020;59(1):197-207.
16. Li X, Li X, Chen S, et al. TRAP1 shows clinical significance in the early diagnosis of small cell lung cancer. *J Inflamm Res*. 2021;14(1):2507-2514.
17. Riaz SP, Luchtenborg M, Coupland VH, et al. Trends in incidence of small cell lung cancer and all lung cancer. *Lung Cancer*. 2012;75(3):280-284. doi:10.1016/j.lungcan.2011.08.004
18. Dolati S, Soleymani J, Kazem SS, et al. The trends in nanomaterial-based biosensors for detecting critical biomarkers in stroke. *Clin Chim Acta*. 2021;514(34):107-121.
19. Quoix E, Purohit A, Faller-Beau M, et al. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. *Lung Cancer*. 2000;30(2):127-134.

How to cite this article: Liu Y, Hu T, Li X, et al. Application of collagen triple helix repeat containing-1 and mitotic spindle apparatus antibody in small cell lung cancer diagnosis. *J Clin Lab Anal*. 2022;36:e24412. doi:10.1002/jcla.24412